The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
22
01
2021
revised:
26
05
2021
accepted:
28
07
2021
pubmed:
11
8
2021
medline:
17
3
2022
entrez:
10
8
2021
Statut:
ppublish
Résumé
INFORM is a prospective, multinational registry gathering clinical and molecular data of relapsed, progressive, or high-risk pediatric patients with cancer. This report describes long-term follow-up of 519 patients in whom molecular alterations were evaluated according to a predefined seven-scale target prioritization algorithm. Mean turnaround time from sample receipt to report was 25.4 days. The highest target priority level was observed in 42 patients (8.1%). Of these, 20 patients received matched targeted treatment with a median progression-free survival of 204 days [95% confidence interval (CI), 99-not applicable], compared with 117 days (95% CI, 106-143;
Identifiants
pubmed: 34373263
pii: 2159-8290.CD-21-0094
doi: 10.1158/2159-8290.CD-21-0094
pmc: PMC9414287
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2764-2779Commentaires et corrections
Type : CommentIn
Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
Pediatr Blood Cancer. 2011 Oct;57(4):549-53
pubmed: 21442722
Eur J Cancer. 2011 Jan;47(1):90-7
pubmed: 20970323
J Natl Cancer Inst. 2017 May 1;109(5):
pubmed: 28376230
Cancer Discov. 2021 Nov;11(11):2780-2795
pubmed: 34112699
Neuro Oncol. 2011 Oct;13(10):1049-58
pubmed: 21784756
J Clin Oncol. 2001 May 1;19(9):2390-6
pubmed: 11331317
Nat Commun. 2021 Jan 21;12(1):498
pubmed: 33479225
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Eur J Cancer. 2016 Sep;65:91-101
pubmed: 27479119
JAMA Oncol. 2016 May 01;2(5):608-615
pubmed: 26822149
Clin Cancer Res. 2017 Oct 15;23(20):6101-6112
pubmed: 28733441
Cancer Discov. 2021 Mar;11(3):545-559
pubmed: 33277309
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622
Drug Saf. 2019 Nov;42(11):1343-1351
pubmed: 31302896
Lancet Oncol. 2018 May;19(5):705-714
pubmed: 29606586
Pediatr Blood Cancer. 2017 Mar;64(3):
pubmed: 27748023
Oncotarget. 2017 Jul 25;8(30):48794-48806
pubmed: 27447864
Pediatr Blood Cancer. 2014 Jul;61(7):1195-201
pubmed: 24615997
Eur J Cancer. 2016 Nov;67:130-140
pubmed: 27662616
Nature. 2018 Mar 15;555(7696):371-376
pubmed: 29489755
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
J Pediatr Hematol Oncol. 2015 Mar;37(2):e102-10
pubmed: 25171452
Haematologica. 2014 Sep;99(9):1472-8
pubmed: 24763401
Nat Med. 2020 Nov;26(11):1742-1753
pubmed: 33020650
Curr Opin Pediatr. 2018 Feb;30(1):17-24
pubmed: 29189430
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
J Pediatr Hematol Oncol. 2009 Sep;31(9):651-63
pubmed: 19707161
Lancet Oncol. 2013 Nov;14(12):1200-7
pubmed: 24140199
J Clin Oncol. 2011 Aug 20;29(24):3286-92
pubmed: 21768459
BMC Cancer. 2020 Jun 5;20(1):523
pubmed: 32503469
J Clin Oncol. 2005 Jan 20;23(3):559-68
pubmed: 15659502
J Clin Oncol. 2008 May 10;26(14):2384-9
pubmed: 18467730
Int J Cancer. 2019 Dec 1;145(11):2996-3010
pubmed: 31008532